Exisulind Versus Placebo After Surgical Removal of the Prostate

Summary

This is a study in which patients with prostate cancer treated by surgical removal of the prostate and considered to be at risk for prostate cancer recurrence will receive Exisulind 250 mg twice a day or placebo twice a day for two years.

Timeline

Start

2003-02

Primary completion

2007-05

Completion

2008-05

Drugs

Indications